CHEMIOTERAPIA, IMMUNOTERAPIA, E TERAPIA DI SUPPORTO DELLE METASTASI CEREBRALI

Translated title of the contribution: Chemotherapy, immunotherapy and support therapy in metastatic brain tumors

G. Robustelli Della Cuna, P. Preti, L. Pavesi, G. A. Da Prada, R. Knerich, G. Butti

Research output: Contribution to journalArticle

Abstract

When a malignant tumor spreads to the brain, its concurrent growth outside of the central nervous system (CNS) and the devastating effects of cerebral metastases often cancel all therapeutic attempts. The disappointing results commonly achieved in the management of intracranial metastases are only partly explained by the low efficacy of available therapeutic modalities. Support therapy plays a major role in the management of patients harboring cerebral metastases. Corticosteroids and osmotic agents can rapidly improve neurological symptoms, allowing a rapid, even if frequently brief, amelioration of the quality of life. Immunotherapy cannot be considered as an effective therapeutic tool for metastatic brain tumors. For many years chemotherapy has been thought inadequate treatment for both controlling the growth of metastases and improving neurological impairment. However, new concepts of multimodality therapy of primary CNS tumors seem to be applicable even to intracranial metastases. In combination with corticosteroids and radiation therapy, nitrosourea compounds (BCNU and CCNU) proved to be effective in more than 1/3 of patients in prolonging survival. New possibilities of improving available results are expected from new antiproliferative drugs (cisplatin) and from new modalities of administering conventional cytotoxic agents (intra-arterial route).

Original languageItalian
Pages (from-to)1387-1394
Number of pages8
JournalMinerva Medica
Volume75
Issue number22-23
Publication statusPublished - 1984

Fingerprint

Brain Neoplasms
Immunotherapy
Neoplasm Metastasis
Drug Therapy
Nitrosourea Compounds
Adrenal Cortex Hormones
Lomustine
Play Therapy
Therapeutics
Carmustine
Central Nervous System Neoplasms
Cytotoxins
Growth
Cisplatin
Radiotherapy
Central Nervous System
Quality of Life
Survival
Brain
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Robustelli Della Cuna, G., Preti, P., Pavesi, L., Da Prada, G. A., Knerich, R., & Butti, G. (1984). CHEMIOTERAPIA, IMMUNOTERAPIA, E TERAPIA DI SUPPORTO DELLE METASTASI CEREBRALI. Minerva Medica, 75(22-23), 1387-1394.

CHEMIOTERAPIA, IMMUNOTERAPIA, E TERAPIA DI SUPPORTO DELLE METASTASI CEREBRALI. / Robustelli Della Cuna, G.; Preti, P.; Pavesi, L.; Da Prada, G. A.; Knerich, R.; Butti, G.

In: Minerva Medica, Vol. 75, No. 22-23, 1984, p. 1387-1394.

Research output: Contribution to journalArticle

Robustelli Della Cuna, G, Preti, P, Pavesi, L, Da Prada, GA, Knerich, R & Butti, G 1984, 'CHEMIOTERAPIA, IMMUNOTERAPIA, E TERAPIA DI SUPPORTO DELLE METASTASI CEREBRALI', Minerva Medica, vol. 75, no. 22-23, pp. 1387-1394.
Robustelli Della Cuna G, Preti P, Pavesi L, Da Prada GA, Knerich R, Butti G. CHEMIOTERAPIA, IMMUNOTERAPIA, E TERAPIA DI SUPPORTO DELLE METASTASI CEREBRALI. Minerva Medica. 1984;75(22-23):1387-1394.
Robustelli Della Cuna, G. ; Preti, P. ; Pavesi, L. ; Da Prada, G. A. ; Knerich, R. ; Butti, G. / CHEMIOTERAPIA, IMMUNOTERAPIA, E TERAPIA DI SUPPORTO DELLE METASTASI CEREBRALI. In: Minerva Medica. 1984 ; Vol. 75, No. 22-23. pp. 1387-1394.
@article{9b56f7e6024c4995a5da0c1d36e7b20f,
title = "CHEMIOTERAPIA, IMMUNOTERAPIA, E TERAPIA DI SUPPORTO DELLE METASTASI CEREBRALI",
abstract = "When a malignant tumor spreads to the brain, its concurrent growth outside of the central nervous system (CNS) and the devastating effects of cerebral metastases often cancel all therapeutic attempts. The disappointing results commonly achieved in the management of intracranial metastases are only partly explained by the low efficacy of available therapeutic modalities. Support therapy plays a major role in the management of patients harboring cerebral metastases. Corticosteroids and osmotic agents can rapidly improve neurological symptoms, allowing a rapid, even if frequently brief, amelioration of the quality of life. Immunotherapy cannot be considered as an effective therapeutic tool for metastatic brain tumors. For many years chemotherapy has been thought inadequate treatment for both controlling the growth of metastases and improving neurological impairment. However, new concepts of multimodality therapy of primary CNS tumors seem to be applicable even to intracranial metastases. In combination with corticosteroids and radiation therapy, nitrosourea compounds (BCNU and CCNU) proved to be effective in more than 1/3 of patients in prolonging survival. New possibilities of improving available results are expected from new antiproliferative drugs (cisplatin) and from new modalities of administering conventional cytotoxic agents (intra-arterial route).",
author = "{Robustelli Della Cuna}, G. and P. Preti and L. Pavesi and {Da Prada}, {G. A.} and R. Knerich and G. Butti",
year = "1984",
language = "Italian",
volume = "75",
pages = "1387--1394",
journal = "Minerva Medicolegale e Archivio di Antropologia Criminale",
issn = "0026-4806",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "22-23",

}

TY - JOUR

T1 - CHEMIOTERAPIA, IMMUNOTERAPIA, E TERAPIA DI SUPPORTO DELLE METASTASI CEREBRALI

AU - Robustelli Della Cuna, G.

AU - Preti, P.

AU - Pavesi, L.

AU - Da Prada, G. A.

AU - Knerich, R.

AU - Butti, G.

PY - 1984

Y1 - 1984

N2 - When a malignant tumor spreads to the brain, its concurrent growth outside of the central nervous system (CNS) and the devastating effects of cerebral metastases often cancel all therapeutic attempts. The disappointing results commonly achieved in the management of intracranial metastases are only partly explained by the low efficacy of available therapeutic modalities. Support therapy plays a major role in the management of patients harboring cerebral metastases. Corticosteroids and osmotic agents can rapidly improve neurological symptoms, allowing a rapid, even if frequently brief, amelioration of the quality of life. Immunotherapy cannot be considered as an effective therapeutic tool for metastatic brain tumors. For many years chemotherapy has been thought inadequate treatment for both controlling the growth of metastases and improving neurological impairment. However, new concepts of multimodality therapy of primary CNS tumors seem to be applicable even to intracranial metastases. In combination with corticosteroids and radiation therapy, nitrosourea compounds (BCNU and CCNU) proved to be effective in more than 1/3 of patients in prolonging survival. New possibilities of improving available results are expected from new antiproliferative drugs (cisplatin) and from new modalities of administering conventional cytotoxic agents (intra-arterial route).

AB - When a malignant tumor spreads to the brain, its concurrent growth outside of the central nervous system (CNS) and the devastating effects of cerebral metastases often cancel all therapeutic attempts. The disappointing results commonly achieved in the management of intracranial metastases are only partly explained by the low efficacy of available therapeutic modalities. Support therapy plays a major role in the management of patients harboring cerebral metastases. Corticosteroids and osmotic agents can rapidly improve neurological symptoms, allowing a rapid, even if frequently brief, amelioration of the quality of life. Immunotherapy cannot be considered as an effective therapeutic tool for metastatic brain tumors. For many years chemotherapy has been thought inadequate treatment for both controlling the growth of metastases and improving neurological impairment. However, new concepts of multimodality therapy of primary CNS tumors seem to be applicable even to intracranial metastases. In combination with corticosteroids and radiation therapy, nitrosourea compounds (BCNU and CCNU) proved to be effective in more than 1/3 of patients in prolonging survival. New possibilities of improving available results are expected from new antiproliferative drugs (cisplatin) and from new modalities of administering conventional cytotoxic agents (intra-arterial route).

UR - http://www.scopus.com/inward/record.url?scp=0021249786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021249786&partnerID=8YFLogxK

M3 - Articolo

VL - 75

SP - 1387

EP - 1394

JO - Minerva Medicolegale e Archivio di Antropologia Criminale

JF - Minerva Medicolegale e Archivio di Antropologia Criminale

SN - 0026-4806

IS - 22-23

ER -